Male Sexual Impotence: a Case Study in Evaluation and Treatment

Total Page:16

File Type:pdf, Size:1020Kb

Male Sexual Impotence: a Case Study in Evaluation and Treatment FAMILY PRACTICE GRAND ROUNDS Male Sexual Impotence: A Case Study in Evaluation and Treatment John G. Halvorsen, MD, MS, Craig Mommsen, MD, James A. Moriarty, MD, David Hunter, MD, Michael Metz, PhD, and Paul Lange, MD Minneapolis, Minnesota R. JOHN HALVORSEN {Assistant Professor, De­ cavernosa. There is also a very important suspensory lig­ D partment o f Family Practice and Community ament—a triangular structure attached at the base of the Health)-. Male sexual impotence is the inability to obtain penis and to the pubic arch blending with Buck’s fascia and sustain an erection adequate to permit satisfactory around the penis—that is responsible for forming the angle penetration and completion of sexual intercourse. Im­ of the erect penis. potence is defined as primary if erections have never oc­ The arterial supply to the penis flows from the aorta curred, and secondary if they have previously occurred through the common iliac, hypogastric, and internal pu­ but subsequently have ceased. The cause of sexual im­ dendal systems. The artery of the penis is a branch of the potence may be psychogenic, organic, or mixed. In the internal pudendal artery and has four branches. The first past, the common belief was that 90 percent of impotence branch, the artery to the bulb, supplies the corpus spon­ was psychological.1,2 Recent research indicates, however, giosum, the glans, and the bulb. The second branch is the that over one half of men with impotence suffer from an urethral artery. The artery of the penis then terminates organic disorder, although often there is considerable into the dorsal artery of the penis (which supplies the deep overlap between both psychological and organic causes.3,4 fascia, the penile skin, and the frenulum) and the deep or A knowledge of the anatomy of the penis and the com­ profunda branch (which supplies the corpora cavernosa plex physiology of erection is necessary to understand the on each side). cause of the problem, the methods of diagnosis, and the The venous drainage consists of both a superficial and treatment options. a deep venous system. The superficial dorsal vein drains into the external pudendal vein, which then connects to the saphenous system. The corpora cavernosa and the ANATOMY AND PHYSIOLOGY corpus spongiosum flow into the deep dorsal vein, which drains into a plexus of veins called the lateral prostatic The three major parts of the penis are (1) the base, which vesical venous plexus, or Santorini’s plexus. is anchored to the perineum; (2) the body, composed of The penis has somatic, sympathetic, and parasympa­ the paired corpora cavernosa located dorsally, and the cor­ thetic innervation. These fibers originate from two areas— pus spongiosum, located ventrally; and (3) the terminal spinal segments T-12 through L-2 and segments S-2 portion, the glans, an enlargement of the tip of the corpus through S-4. The afferent somatic fibers responsible for spongiosum. The corpora cavernosa are separated by an penile sensation travel through the dorsal nerve of the incomplete connective tissue septum that permits free penis to the internal pudendal nerve back to its spinal communication of blood between the corpora and that roots S-2 through S-4. These fibers supply the ischiocav­ allows them to function as a central unit. They are also ernous muscle, the bulbocavernous muscle, penile skin, fused in the body and proximally diverge to attach to the and urogenital diaphragm. The parasympathetic fibers, inferior aspect of the pubic rami. The corpus spongiosum on the other hand, originate from the anterior roots of S- houses the urethra and lies ventral between the corpora 2, S-3, and S-4, and are known as the nervi erigentes. They terminate in the small and large cavernous nerves supplying the penis. The sympathetic fibers originate from Submitted, revised, September 29, 1988 the spinal roots of T-12 through L-2, descending through From the Departments of Family Practice and Community Health, Neurology, the aortic plexus, the superior hypogastric plexus, the in­ Radiology and Urology, University of Minnesota, Minneapolis, Minnesota. Re­ ferior hypogastric nerves, and finally intermingling with quests for reprints should be addressed to: Dr. John G. Halvorsen, 516 Delaware St, SE, Box 718 UMHC, Minneapolis, MN 55455. the parasympathetic nerves as they reach the penis itself. 1988 Appleton & Lange THE JOURNAL OF FAMILY PRACTICE, VOL. 27, NO. 6: 583-594, 1988 583 MALE SEXUAL IMPOTENCE Physiologically, erection involves a neurologically me­ Additional history obtained during his initial visit to diated series of events that subsequently give rise to com­ our clinic indicated that he was sexually competent and plex vascular events that result in increased size and ri­ had achieved orgasm with a normal erection a day before gidity of the penis. The single, most basic factor producing his injury. His previous workup had included a “stamp an erection is that more blood must enter than leave the test,” which is a crude snap gauge test to measure noc­ cavernous spaces. turnal penile tumescence. This test showed no evidence Psychogenic erections are cortically mediated by sight, of tumescence. sound, smell, and thought. The exact neurotransmitter On initial physical examination Mr. J. was moderately mechanisms involved are poorly defined, but it is believed anxious. His blood pressure was slightly elevated at 160/ that both dopamine and serotonin are important. Tes­ 90 mmHg. His heart rate was 72 beats per minute and tosterone is also needed for libido and ejaculation. Cortical his weight 204 pounds. His genitourinary examination stimuli exit first through the preoptic region of the hy­ was normal. Neurologically he had an absent bulbocav­ pothalamus, then through the pons and cord, exiting ernous reflex and decreased proprioception in his left great through T-12 and L-2. Reflex erections occur by way of toe. Vascular examination revealed absent dorsalis pedis the sacral reflex. The afferent limb arises from somatic pulses bilaterally and absent penile pulses even with the fibers S-2 through S-4 by way of the pudendal nerve as vascular doptone. No penile blood pressure was detectable. previously mentioned, and the efferent limb (the para­ His medical history included multiple problems. Med­ sympathetic limb) exits through the nervi erigentes from ications included oral testosterone, as previously noted, S-2 to S-4. There is complex mingling of sympathetic and as well as a ,8-blocker used to treat his hypertension, which parasympathetic fibers so that in the neurologically intact had been only moderately well controlled. He had also individual both psychogenic and reflex pathways act syn- been treated for alcohol abuse in 1970 at the Veterans ergistically for erection to occur. The exact biochemical Administration hospital. Chart notes by the psychologist mechanisms that enable these neurologic signals to in­ at the clinic where he was initially evaluated indicated crease blood flow to the corpora are yet to be completely that he might again be chemically dependent, but he had defined, although adrenergic transmitters seem to be more refused treatment. He had also sustained a back injury at important than cholinergic. Vasoactive intestinal peptides work in 1975 and had undergone a subsequent laminec­ may also play an important role. tomy at the L-4-L-5 level. He had had chronic back pain After this basic science review, Dr. Craig Mommsen, and a stiff knee since that time. Both of these factors pre­ the family practice resident who coordinated the patient’s cipitated his early retirement from his machine shop oc­ evaluation, will present the history and examination ob­ cupation. He also had been a tobacco user at greater than tained on the first visit to our clinic. one pack per day for over 20 years. He indicated that he had experienced some anxiety and possibly a slight ele­ ment of depression; however, these problems had not been CASE PRESENTATION treated. The only other additional information obtained during his initial visit to the clinic was a random blood DR. CRAIG MOMMSEN {Third-year Resident in Family glucose of 105 mg/dL, which was within normal limits. Practice, University o f Minnesota, University Family After the initial visit with him, the problem list, shown Practice Unit)-. Mr. J., a 56-year-old gentleman whose chief in Table 1, suggested multiple possible causes for his im­ complaint was the inability to obtain erections after having potence. These involved psychologic factors, neurogenic slipped and fallen, appeared at the University of Min­ and vascular factors, and the possibility of medication nesota Family Practice Clinic three years after his fall. He side effects. The patient, therefore, had further evaluation had slipped on the ice, fractured his left patella, and driven from a neurological, psychological, and vascular perspec­ his left foot into his perineum. Since that fall he had not tive. Dr. Michael Metz, from the Program in Human Sex­ had any erections, but he had been able to ejaculate with uality at the University of Minnesota, will first address manual stimulation. He had had a partial evaluation at the psychological causes for impotence. another clinic prior to visiting the University Family Practice Clinic. This evaluation indicated a low, or bor­ derline low, testosterone level, and he was given a trial on PSYCHOLOGICAL EVALUATION oral testosterone in an attempt to improve his sexual function. He was also evaluated by a psychologist, who DR. MICHAEL METZ {Assistant Professor, Department thought he did not have a significant psychological cause of Family Practice and Community Health): At this time, for his impotence. Despite these measures, his impotence I will discuss the psychological variables that must be had persisted and had continued to concern him and his considered in evaluating a patient with impotence.
Recommended publications
  • Functional Anatomy of the Hypothalamic–Pituitary–Gonadal Axis and 1 the Male Reproductive Tract
    Cambridge University Press 978-1-107-01212-7 - Fertility Preservation in Male Cancer Patients Editor-in-Chief John P. Mulhall Excerpt More information Section 1 Anatomy and physiology Chapter Functional anatomy of the hypothalamic–pituitary–gonadal axis and 1 the male reproductive tract Nelson E. Bennett Jr. Anatomy of reproductive function The reproductive functional axis of the male can be divided into three major subdivisions: (1) the hypo- thalamus, (2) the pituitary gland, and (3) the testis. Each level elaborates a signal, or transmitter molecule, that stimulates or inhibits the subsequent level of the axis. The end result is the production and expulsion of semen that contains spermatozoa. This chapter exam- ines the hypothalamic–pituitary–gonadal (HPG) axis, and reviews the functional anatomy of the testis, epi- didymis, vas deferens, seminal vesicles, prostate, and penis. Hypothalamus and anterior pituitary gland The control of male sexual and reproductive func- tion begins with secretion of gonadotropin-releasing hormone (GnRH) by the hypothalamus (Fig. 1.1). This hormone in turn stimulates the anterior pituitary gland to secrete two downstream hormones (termed gonadotropins). These hormones are luteinizing hor- mone (LH) and follicle-stimulating hormone (FSH). LH is the primary stimulus for the testicular secre- tion of testosterone, while FSH mainly stimulates spermatogenesis. Gonadotropin-releasing hormone (GnRH) Figure 1.1. Feedback regulation of the hypothalamic– The neuronal cells of the arcuate nuclei of the hypo- pituitary–gonadal (HPG) axis in males. Positive (stimulatory) effects are shown by + and inhibitory (negative feedback) effects by –. thalamus secrete GnRH, a 10-amino-acid peptide. The GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone; endingsoftheseneuronsterminateinthemedian FSH, follicle-stimulating hormone.
    [Show full text]
  • Transurethral Alprostadil with MUSETM (Medicated
    International Journal of Impotence Research (1997) 9, 187±192 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 Transurethral Alprostadil with MUSETM (medicated urethral system for erection) vs intracavernous AlprostadilÐa comparative study in 103 patients with erectile dysfunction H Porst Urological Of®ce, Neuer Jungfernstieg 6a, 20354 Hamburg, Germany A comparative study in 103 unselected patients with erectile dysfunction between MUSETM up to 1000 mg and intracavernous Alprostadil (ProstavasinTM)upto20mg provided total response-rates of 43% (MUSETM) vs 70% (ProstavasinTM). Complete rigid erections were reached in 10% (MUSETM) vs 48% (ProstavasinTM). The average end-diastolic ¯ow values in the deep penile arteries ranged between 9.2±9.4 cm/s after MUSETM and 4.5±4.8 cm/s after i.c. Alprostadil con®rming the investigator's assessment, that in the vast majority of patients MUSETM were not able to induce a complete cavernous smooth muscle relaxation. In terms of side effects the reported penile pain/burning-rate after MUSETM was 31.4% compared to 10.6% after i.c. Alprostadil. In addition after MUSETM clinically relevant systemic side-effects like dizziness, sweating and hypotension occurred in 5.8% with syncope in 1%. No circulatory side-effects were encountered after i.c. Alprostadil. Urethral bleeding after MUSETM-application was observed in 4.8%. Due to the superior ef®cacy and lower side-effects self-injection therapy with Alprostadil remains the `Gold Standard' in the management of male impotence. MUSETM should be reserved
    [Show full text]
  • Current Status of Local Penile Therapy
    International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Current status of local penile therapy F Montorsi1*, A Salonia1, M Zanoni1, P Pompa1, A Cestari1, G Guazzoni1, L Barbieri1 and P Rigatti1 1Department of Urology, University Vita e Salute – San Raffaele, Milan, Italy Guidelines for management of patients with erectile dysfunction indicate that intraurethral and intracavernosal injection therapies represent the second-line treatment available. Efficacy of intracavernosal injections seems superior to that of the intraurethral delivery of drugs, and this may explain the current larger diffusion of the former modality. Safety of these two therapeutic options is well established; however, the attrition rate with these approaches is significant and most patients eventually drop out of treatment. Newer agents with better efficacy-safety profiles and using user-friendly devices for drug administration may potentially increase the long-term satisfaction rate achieved with these therapies. Topical therapy has the potential to become a first- line treatment for erectile dysfunction because it acts locally and is easy to use. At this time, however, the crossing of the barrier caused by the penile skin and tunica albuginea has limited the efficacy of the drugs used. International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81. DOI: 10.1038= sj=ijir=3900808 Keywords: erectile dysfunction; local penile therapy; topical therapy; alprostadil Introduction second patient category might be represented by those requesting a fast response, which cannot be obtained by sildenafil; however, sublingual apomor- Management of patients with erectile dysfunction phine is characterized by a fast onset of action and has been recently grouped into three different may represent an effective solution for these 1 levels.
    [Show full text]
  • Trimix Injection Information for Patients
    Individualized Medications to Fit Your Needs 5 0 3 BEXCELLENCEYOUCANRELYON TRIMIX INJECTION PHYSCIAN INFORMATION WWW.OLYMPIAPHARMACY.COM TriMix Injection Physician Information TriMix injections are an alternative to PDE5 Inhibitor tablets (Viagra®, Levitra®, Cialis®) and most commonly include the mixture of 3 drugs; phentolamine, papaverine and alprostadil. TriMix is especially useful when patients are unable to take PDE5 Inhibitors because they are taking nitrates, certain beta blockers, or experience severe side effects from the oral medications. Alternative to Tablets TriMix injections are an alternative to PDE5 Inhibitor tablets (Viagra®, Levitra®, Cialis®) and most commonly include the mixture of 3 drugs; phentolamine, papaverine and alprostadil. TriMix is especially useful when patients are unable to take PDE5 Inhibitors because they are taking nitrates, certain beta blockers, or experience severe side effects from the oral medications How It Works: An intracavernous injection, is the most effective non-surgical treatment for ED, according to the American Urologic Association. Injections into the penis, unlike oral medications, trigger an automatic erection in less than 5 minutes. TriMix is a mixture of three vasodilators that when injected, cause the corpus cavernosum to relax, expand and fill with blood, creating a powerful erection Dosage: The initial dose should be 0.1 cc Wait 3 days before increasing dosage. Increase by 0.025 cc until a satisfactory dose is reached. The maximum dose is 0.50 cc. Do not be discouraged by a poor result with the first few injections, as the initial dose has been kept low to avoid a prolonged erection Reversing The Test Dose: Phenylephrine is commonly used to reverse the effects of TriMix to prevent an erection lasting too long while the patient is learning their correct dosage.
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH PrCAVERJECT® STERILE POWDER (Alprostadil for Injection) 20 mcg Vials Prostaglandin Pfizer Canada Inc. Date of Revision: 17,300 Trans-Canada Highway June 01, 2016 Kirkland, Quebec H9J 2M5 Control No. 193414 ® TM Pharmacia Enterprises SARL Pfizer Canada Inc., Licensee Pfizer Canada Inc. 2016 PRODUCT MONOGRAPH PrCAVERJECT STERILE POWDER (Alprostadil for Injection) Prostaglandin ACTION AND CLINICAL PHARMACOLOGY Alprostadil is a prostaglandin with various pharmacological actions that include vasodilation and inhibition of platelet aggregation, inhibition of gastric secretion, stimulation of intestinal smooth muscle and stimulation of uterine smooth muscle. Alprostadil, when given to impotent men by intracavernous injection, induces erections within 5 to 20 minutes after administration. The duration of erection is dose-dependent. The mechanism of penile erection involves a complex series of neurovascular events. Alprostadil injected intracavernosally causes tumescence by increasing cavernous blood flow through relaxation of trabecular smooth muscle and dilation of cavernosal arteries. With regards to the action of alprostadil on penile structures, in most animal species tested, alprostadil had relaxant effects on retractor penis and corpus cavernosum urethrae in vitro. Alprostadil also relaxed isolated preparations of human corpus cavernosum and spongiosum as well as cavernous arterial segments previously contracted by either noradrenaline or PGF2α. In pigtail monkeys (Macaca nemestrina), alprostadil increased cavernous arterial blood flow in vivo. The degree and duration of cavernous smooth muscle relaxation in this animal model was dose-dependent. Other actions of PGE1 involve the cardiovascular system, central nervous system (CNS), autonomic nervous system, respiratory system, gastrointestinal system and hematopoietic system. Pharmacokinetics Absorption The absolute bioavailability of alprostadil following intracavernosal injection has not been determined.
    [Show full text]
  • Vascularization of the Penis of a Man
    Roczniki Akademii Medycznej w Białymstoku · Vol. 49, 2004 · Annales Academiae MedicaeVascularization Bialostocensis of the penis of a man 285 Vascularization of the penis of a man Okolokulak E, Volchkevich D The Human Anatomy Department, Grodno State Medical University, Grodno, Belarus Abstract Conclusions: The penis receives blood from external and internal pudendal arteries, which are very variable. The Purpose: The study of the features of the blood supply of venous blood of the penis flows off in three types of veins. a penis of the man. Material and methods: Macromicropreparation, angio- graphy, corrosion method, morphometry, statistical method. Key words: penis, veins of penis, arteries of penis, erectile Results: The penis has three venous collector-execut- dysfunction. ing outflow of blood. First of them is submitted surface dorsal vein, which is shaped from small-sized venous ves- sels of skin, subcutaneous fat and surface fascia of penis. Introduction The beginning deep dorsal vein, which will derivate second venous collector, gives veniplex of head of the penis. The The development of the medical technology has deepened spongy veins outstanding as third venous collector, reach the knowledge of organic violations of gears of erection. It was the bulb of penis, where they receive small-sized bulbar vein. straightened out, that more than 50% from them cause vascular The arterial blood supply of penis happens at the expense of disorders [1-4]. It has given a particular push to more detailed external and internal pudendal arteries. The external puden- learning extra- and intraorgans vessels of the penis. At the same dal artery starts from an internal wall of femoral artery on time, the problems of vascularization and relationships of blood 2.5-2.7 cm below inguinal ligament.
    [Show full text]
  • (Medical and Mechanical) Treatment of Erectile Dysfunction
    130 SOP Conservative (Medical and Mechanical) Treatment of Erectile Dysfunctionjsm_12023 130..171 Hartmut Porst, MD,* Arthur Burnett, MD, MBA, FACS,† Gerald Brock, MD, FRCSC,‡ Hussein Ghanem, MD,§ Francois Giuliano, MD,¶ Sidney Glina, MD,** Wayne Hellstrom, MD, FACS,†† Antonio Martin-Morales, MD,‡‡ Andrea Salonia, MD,§§ Ira Sharlip, MD,¶¶ and the ISSM Standards Committee for Sexual Medicine *Private Urological/Andrological Practice, Hamburg, Germany; †The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA; ‡Division of Urology, University of Western, ON, Canada; §Sexology & STDs, Cairo University, Cairo, Egypt; ¶Neuro-Urology-Andrology Unit, Department of Physical Medicine and Rehabilitation, Raymond Poincaré Hospital, Garches, France; **Instituto H.Ellis, São Paulo, Brazil; ††Department of Urology, Section of Andrology and Male Infertility, Tulane University School of Medicine, New Orleans, LA, USA; ‡‡Unidad Andrología, Servicio Urología Hospital, Regional Universitario Carlos Haya, Málaga, Spain; §§Department of Urology & Urological Reseach Institute (URI), Universiti Vita Saluta San Raffaele, Milan, Italy; ¶¶University of California at San Francisco, San Francisco, CA, USA DOI: 10.1111/jsm.12023 ABSTRACT Introduction. Erectile dysfunction (ED) is the most frequently treated male sexual dysfunction worldwide. ED is a chronic condition that exerts a negative impact on male self-esteem and nearly all life domains including interper- sonal, family, and business relationships. Aim. The aim of this study
    [Show full text]
  • Isoflurane Inhalation Anesthesia Should Be a New Requirement In
    www.nature.com/scientificreports OPEN Isofurane inhalation anesthesia should be a new requirement in intracavernosal pressure Received: 21 December 2016 Accepted: 19 October 2017 detection—the gold standard of Published: xx xx xxxx erectile function assessment Jinhong Li1,2, Changjing Wu1, Fudong Fu1, Xuanhe You1, Liang Gao1,2, Romel Wazir3, Feng Qin1, Ping Han2 & Jiuhong Yuan1,2 Intracavernosal pressure (ICP) is gold standard for the detection of erectile function in animals, but no consensus has yet been achieved on what kind of anesthetic protocol should be applied. A total of 16 adult male Sprague-Dawley rats were randomized into two groups. In group A, chloral hydrate was injected intraperitoneally. Rats in group B were induced in 5% isofurane for 3 min and then maintained in 1.0–1.5% isofurane. Mean arterial pressure (MAP), respiratory rate (RR) and heart rate were monitored during all experiments. After ICP detection, tail vein and carotid artery blood were collected. The maximum ICP value, MAP and ICP/MAP ratio in group B was signifcantly higher than in that of group A. The RR in group A was lower than in that of group B, but the heart rate in group A was higher than in group B. There were no signifcant diferences in both pO2 and pCO2 between groups. While the data showed that animals in group A were relatively hypoxemic. Isofurane inhalation anesthesia in detection of erectile function could ofer a relatively more stable physical state than in that under the efect of chloral hydrate intraperitoneal anesthesia. Isofurane inhalation anesthesia is more suitable for ICP test.
    [Show full text]
  • Priapism After Epidural Or Spinal Anesthesia
    Western Michigan University ScholarWorks at WMU Research Day WMU Homer Stryker M.D. School of Medicine 2017 Priapism After Epidural or Spinal Anesthesia Sarah Khalil Western Michigan University Homer Stryker M.D. School of Medicine Kelly Quesnelle Western Michigan University Homer Stryker M.D. School of Medicine Jeffrey Friedman Western Michigan University Homer Stryker M.D. School of Medicine Audrey Jensen Western Michigan University Homer Stryker M.D. School of Medicine Duncan Polot Western Michigan University Homer Stryker M.D. School of Medicine See next page for additional authors Follow this and additional works at: https://scholarworks.wmich.edu/medicine_research_day Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons WMU ScholarWorks Citation Khalil, Sarah; Quesnelle, Kelly; Friedman, Jeffrey; Jensen, Audrey; Polot, Duncan; and Spitler, Sydney, "Priapism After Epidural or Spinal Anesthesia" (2017). Research Day. 77. https://scholarworks.wmich.edu/medicine_research_day/77 This Abstract is brought to you for free and open access by the WMU Homer Stryker M.D. School of Medicine at ScholarWorks at WMU. It has been accepted for inclusion in Research Day by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. Authors Sarah Khalil, Kelly Quesnelle, Jeffrey Friedman, Audrey Jensen, Duncan Polot, and Sydney Spitler This abstract is available at ScholarWorks at WMU: https://scholarworks.wmich.edu/medicine_research_day/77 Priapism After Epidural and
    [Show full text]
  • Let's Talk About ED
    LET’S TALK ABOUT ED Get the facts. And get back to your life. This content is intended for patient counseling purposes only. This content is for informational/educational purposes and is not intended to treat or diagnose any disease or person. No claims are made as to the safety or eicacy of mentioned preparations. The compounded medications featured in this piece have been prescribed and administered by physicians who work with Wedgewood Pharmacy. You are encouraged to speak with your health care provider as to the appropriate use of any medication. TELL ED TO TAKE A HIKE 2 Let’s Talk About ED You’re not alone. A lot of guys know ED. Nearly More than % 30million 50 men have erectile of men between the ages dysfunction (ED) in the of 40 and 70 experience United States. it to some degree1. The bottom line is this – you’re not alone, and you don’t have to go it alone. This guide focuses on a treatment option prescribed for erectile dysfunction, penile self-injection medications, also known as intracavernosal injections. If you have any questions after reading this guide, bring them to your doctor’s attention. Don’t let ED be the boss of you. It’s natural to feel some anxiety about erectile dysfunction. But ED is a medical condition that can be treated – and treatment can result in signiicantly improved quality of life2 for both you and your partner. Many men report that enhancing or even saving a relationship, enjoying a satisfying sex life and regaining conidence far outweigh any anxieties about pursuing treatment – it’s well worth it.
    [Show full text]
  • Summary of Product Characteristics
    SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT <Product name>25 micrograms / 2 mg solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION <Product name> 25 micrograms / 2 mg: 1 dose (ampoule 0.35 ml) contains 25 micrograms of aviptadil and 2 mg of phentolamine mesilate. Excipients with known effect: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium- free’. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Appearance: Colorless to pale yellow solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications <Product name> is indicated for the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology. 4.2 Posology and method of administration Posology <Product name> 25 micrograms / 2 mg. The injection should provide the patient with an erection that is satisfactory for sexual intercourse. It is recommended that the duration of the erection does not exceed one hour. Injection frequency should not exceed once daily or 3 times weekly. Paediatric population: <Product name> is not recommended in children. Elderly: No formal studies have been performed in patients above 75 years of age. Impaired renal or hepatic function: No formal studies have been performed in patients with impaired renal or hepatic function. Method of administration The ampoule can be brought to room temperature before use, or it can be used directly from the refrigerator (see section 6.6). The intracavernosal injection must be done under sterile conditions. <Product name> should be administered by direct intracavernous injection.
    [Show full text]
  • Caverjecttm (Alprostadil)
    Pfizer Confidential Disclaimer While these labels are the most current Drug Control Authority (DCA) approved versions of content, these are not necessarily reflective of final printed labeling currently in distribution LPD Title : ALPROSTADIL LPD Date : 14 December 2016 Country : Malaysia Ref. Doc. : UK SmPC Dated November 2016 and UK PIL Dated March 2016 Reason : Addition of text regarding needle breakage to section 4.4 special warnings and precautions for use. To update the storage condition to “Store below 30°C” and section 6.5. Remove 5mcg and 10mcg SKU as product no longer registered 1. NAME OF THE MEDICINAL PRODUCT CAVERJECTTM (ALPROSTADIL) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION CAVERJECT™ 20 μg Each powder vial contains: Alprostadil 20 μg – Lactose monohydrate - Sodium citrate - α-cyclodextrine - Hydrochloric acid - Sodium hydroxide. Each diluent syringe (1 ml) contains: Benzyl alcohol 9 mg - Water for injection. 3. PHARMACEUTICAL FORM Pharmaceutical form after reconstitution: injectable solution. Way of administration: intracavernosal. 4. CLINICAL PARTICULARS Distribution 4.1 Therapeutic Indication Alprostadil is indicated for the treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic or mixed aetiology. Alprostadil may be a useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction. For 4.2 Posology and Method of Administration Alprostadil is administered by direct intracavernous injection. A half inch, 27 to 30 gauge needle is generally recommended. The dose of alprostadil should be individualised for each patient by careful titration under supervision by a physician. The intracavernosal injection must be done under sterile conditions. The site of injection is usually along the dorsolateral aspect of the proximal third of the penis.
    [Show full text]